Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Status:
Completed
Trial end date:
2017-01-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin
(AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem
cell transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)